Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at least 18 years old
- Your cancer must have been confirmed by a tissue test (biopsy) and have a specific genetic change called a KRAS G12C mutation, and it must be advanced or spread to other parts of the body with no curative treatment available
- For the early dose-finding part of the trial: you must have a solid tumor that has already been treated with other therapies
- For the expansion and later phase of the trial: if you have non-small cell lung cancer (NSCLC), you must have previously been treated with immunotherapy, chemotherapy, and a specific type of KRAS G12C-targeting drug; OR if you have another solid tumor, you must have had prior treatment but never received a KRAS G12C-targeting drug before
- You must be generally well enough to carry out daily activities with no or minimal limitations (this is measured by a standard scale called ECOG 0 or 1 — confirm with trial site)
- Your liver, kidneys, and other organs must be working well enough as shown by blood tests
Who may not be able to join:
- You cannot join if your cancer started in the brain or spinal cord
- You cannot join if you currently have active cancer that has spread to the brain
- You cannot join if you have a digestive system problem that would affect how your body absorbs medication (confirm with trial site)
- You cannot join if you have had a major surgery within the past 28 days, or a minor non-study-related procedure within the past 7 days before starting treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Revolution Medicines, Inc., Revolution Medicines, Inc.
Phone: 1-844-2-REVMED
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with adverse events (AEs) in Phase 1b; Changes in vital signs in Phase 1b; Changes in clinical laboratory test values in Phase 1b; Dose Limiting Toxicities in Phase 1b; Changes in ECGs in Phase 1b; Overall Response Rate (ORR) in Phase 2
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.